Micardis HCT is a blood pressure medicine that combines two drugs -- hydrochlorothiazide and Micardis. This eMedTV Web page offers a more in-depth look at the drug, including its uses, effects, dosing information, and potential side effects.
Common Micardis HCT side effects include fatigue, diarrhea, or nausea. As this eMedTV article explains, while most side effects do not require treatment, serious problems, such as wheezing or seizures, should be reported to a doctor immediately.
Micardis HCT uses primarily include the treatment of high blood pressure in adults. This page on the eMedTV Web site discusses whether Micardis HCT is suitable for use in children and explains how the medicine works to lower blood pressure.
The suggested Micardis HCT dosage for treating high blood pressure is 40 mg/12.5 mg, taken once a day. This eMedTV resource explains how your doctor may determine your dosage and offers tips and precautions for taking the medicine.
This eMedTV resource offers a list of drugs that may cause negative Micardis HCT interactions, including digoxin, colestipol, and lithium. These drug interactions may reduce the effectiveness of the medicines or cause certain side effects.
Micardis HCT may potentially make systemic lupus erythematosus worse -- or even cause it. This eMedTV segment offers more Micardis HCT precautions and warnings, including other possible side effects and information on who should not take the drug.
Micardis HCT and pregnancy are a potentially bad combination. As this eMedTV page explains, studies show that the drug may cause harm to a fetus and ultimately lead to developmental problems with the lungs, nervous system, or cardiovascular system.
Symptoms of a Micardis HCT overdose can include dry mouth, increased thirst, weakness, or restlessness. This eMedTV resource lists other possible signs of an overdose and discusses treatment options that are available.
Generic Micardis HCT is currently not available on the market. As this section of the eMedTV Web site explains, however, a generic version of the medicine may become available in 2020, when its first patent with Boehringer Ingelheim expires.
HealthSavvy Sign In
|